Market Size of Europe Molecular Diagnostics Industry
Study Period | 2021 - 2029 |
Market Size (2024) | USD 3.45 Billion |
Market Size (2029) | USD 5.32 Billion |
CAGR (2024 - 2029) | 8.96 % |
Fastest Growing Market | Asia-Pacific |
Largest Market | North America |
Market Concentration | Low |
Major Players*Disclaimer: Major Players sorted in no particular order |
Europe Molecular Diagnostics Market Analysis
The Europe Molecular Diagnostics Market size is estimated at USD 3.45 billion in 2024, and is expected to reach USD 5.32 billion by 2029, growing at a CAGR of 8.96% during the forecast period (2024-2029).
Factors such as the increasing burden of various bacterial and viral epidemics in this region, increasing demand for point-of-care diagnostics, and recent advancements in pharmacogenomics are expected to propel market growth during the forecast period. For instance, in May 2023, the ECCMID congress ELITech Group announced the impending launch of a new high throughput sample-to-result instrument for molecular diagnostics. The company’s new high throughput approach will be based on ELITech’s proven extraction and assay technology.
Further, according to the European Alliance for Personalized Medicine December 2023 factsheet, the United Kingdom has a well-established infrastructure for NGS testing. There are dedicated NGS centers equipped with the necessary tools and infrastructure. Sufficient funding is available to develop and maintain NGS infrastructure, indicating a commitment to advancing this technology. Thus, the availability of infrastructure and advancing technology in Europe is anticipated to increase the adoption of molecular diagnostics in the region.
The market players in the region are concentrating on product and technological development and acquiring technology companies to boost market growth. For instance, in May 2024, Bruker Corporation acquired the ELITechGroup business, excluding the carved-out ELITech clinical chemistry business. ELITech provides systems and assays for molecular diagnostics (MDx), biomedical systems/specialty IVD, and microbiology. Such developments are expected to drive the market.
Therefore, the market is anticipated to achieve high growth rates during the forecast period due to the above factors. However, the need for high-complexity testing centers is expected to hinder market growth during the forecast period.
Europe Molecular Diagnostics Industry Segmentation
Molecular diagnostic tests detect specific sequences in DNA or RNA (including single nucleotide polymorphisms (SNP), deletions, rearrangements, and insertions), which may or may not be associated with diseases.
The European molecular diagnostics market is segmented by technology, application, product, end user, and geography. By technology, the market is segmented into in situ hybridization, chips and microarrays, mass spectrometry (MS), sequencing, PCR, and other technologies. By application, the market is segmented into infectious diseases, oncology, pharmacogenomics, microbiology, genetic disease testing, and other applications. By product, the market is segmented into instruments, reagents, and other products. By end user, the market is segmented into hospitals, laboratories, and other end users. Geographically, the market is segmented into Germany, the United Kingdom, France, Italy, Spain, and the Rest of Europe. The market report also covers the estimated market sizes and trends in Europe. The report offers market size and forecasts in value (USD) for the above segments.
By Technology | |
In Situ Hybridization | |
Chips and Microarrays | |
Mass Spectrometry (MS) | |
Sequencing | |
PCR | |
Other Technologies |
By Application | |
Infectious Diseases | |
Oncology | |
Pharmacogenomics | |
Microbiology | |
Genetic Disease Testing | |
Other Applciations |
By Product | |
Instruments | |
Reagents | |
Other Products |
By End User | |
Hospitals | |
Laboratories | |
Other End Users |
By Geography | |
Germany | |
United Kingdom | |
France | |
Italy | |
Spain | |
Rest of Europe |
Europe Molecular Diagnostics Market Size Summary
The European molecular diagnostics market is poised for significant growth, driven by the increasing adoption of advanced diagnostic technologies such as next-generation sequencing, PCR, and microarrays. The market's expansion is largely attributed to the heightened demand for testing during the COVID-19 pandemic, which underscored the importance of molecular diagnostics in managing infectious diseases. The region's focus on point-of-care diagnostics and advancements in pharmacogenomics further propels market growth. The burden of chronic diseases, including HIV/AIDS and heart conditions, alongside the prevalence of infectious diseases like STIs, continues to drive the demand for molecular diagnostics. Key players in the market are actively engaged in product development and strategic mergers to enhance their market presence and drive innovation.
Germany stands out as a significant contributor to the market's growth, supported by its robust healthcare infrastructure and the presence of global companies specializing in molecular diagnostics. The increasing incidence of chronic conditions, particularly cancer, has spurred demand for diagnostic solutions, contributing to the market's expansion. The competitive landscape in Europe is characterized by a mix of international and regional players, with companies like Abbott Laboratories, Roche, and Illumina leading the charge in innovation and market share. Recent product launches and strategic partnerships highlight the dynamic nature of the market, as companies strive to meet the evolving needs of healthcare providers and patients across the region.
Europe Molecular Diagnostics Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Demand for Point-of-care Diagnostics
-
1.2.2 Advancements in Pharmacogenomics and Other Technologies
-
1.2.3 Possibility of Outbreaks of Bacterial and Viral Epidemics
-
-
1.3 Market Restraints
-
1.3.1 Need for High-complexity Testing Centers
-
-
1.4 Industry Attractiveness - Porter's Five Forces Analysis
-
1.4.1 Bargaining Power of Buyers/Consumers
-
1.4.2 Bargaining Power of Suppliers
-
1.4.3 Threat of New Entrants
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value in USD)
-
2.1 By Technology
-
2.1.1 In Situ Hybridization
-
2.1.2 Chips and Microarrays
-
2.1.3 Mass Spectrometry (MS)
-
2.1.4 Sequencing
-
2.1.5 PCR
-
2.1.6 Other Technologies
-
-
2.2 By Application
-
2.2.1 Infectious Diseases
-
2.2.2 Oncology
-
2.2.3 Pharmacogenomics
-
2.2.4 Microbiology
-
2.2.5 Genetic Disease Testing
-
2.2.6 Other Applciations
-
-
2.3 By Product
-
2.3.1 Instruments
-
2.3.2 Reagents
-
2.3.3 Other Products
-
-
2.4 By End User
-
2.4.1 Hospitals
-
2.4.2 Laboratories
-
2.4.3 Other End Users
-
-
2.5 By Geography
-
2.5.1 Germany
-
2.5.2 United Kingdom
-
2.5.3 France
-
2.5.4 Italy
-
2.5.5 Spain
-
2.5.6 Rest of Europe
-
-
Europe Molecular Diagnostics Market Size FAQs
How big is the Europe Molecular Diagnostics Market?
The Europe Molecular Diagnostics Market size is expected to reach USD 3.45 billion in 2024 and grow at a CAGR of 8.96% to reach USD 5.32 billion by 2029.
What is the current Europe Molecular Diagnostics Market size?
In 2024, the Europe Molecular Diagnostics Market size is expected to reach USD 3.45 billion.